Does Lisinopril increase urination?
By
Dr Natalia Marceli Stephanes (PhD)
Author bio
Dr Natália Marcéli Stephanes PhD is a Pharmacist with expertise in Drugs Administration and Toxicity; Discovery of New Drugs; Cancer Treatment; Biochemical Analyzes and Hematological Analyzes. She writes and reviews content on these topics.
Dr Natália Marcéli Stephanes’ Highlights:
- Pharmacist at the Department of Health of Santa Catarina State, Brazil
- PhD with a focus on oncology treatment
- Years of experience in commercial pharmacy
- Bachelor, Master and PhD degrees in Pharmacy at the Federal University of Santa Catarina
Professional Experience:
From her undergraduate studies to her Master’s and Doctorate degrees in Pharmacy, Dr Natália Marcéli Stephanes has participated in numerous scientific studies in the field of oncology and onco-hematology at the University Hospital of the Federal University of Santa Catarina, Brazil. Her research has focused on understanding the molecular and biochemical bases of malignant neoplasms and investigating safer and more effective therapeutic alternatives.
Dr Natália Marcéli Stephanes has also served as an assistant professor of haematology for undergraduate students at the Federal University of Santa Catarina. Additionally, she held the position of professor of Hospital Pharmacy at the Qualificar Technical School in Brazil, where she developed instructional materials for use in the Pharmacy Postgraduate Program at the Leonardo Da Vinci University Center.
In addition to her academic experiences, Dr Natália Marcéli Stephanes possesses a strong expertise in commercial pharmacy, with in-depth knowledge of medications, their routes of administration, desired effects, adverse effects, and toxicity.
Currently, Dr Natália Marcéli Stephanes works as a Pharmacist at the Health Department of Santa Catarina State, where her role entails providing pharmaceutical scientific consulting services to judges.
Education:
- 2016 Bachelor in Pharmacy at the Federal University of Santa Catarina, Brazil
- 2018 Master in Pharmacy at the Federal University of Santa Catarina, Brazil
- 2023 PhD in Pharmacy at the Federal University of Santa Catarina, Brazil
The main publications of Dr Natália Marcéli Stephanes are:
Falchetti M ; Delgobo M, Zancanaro H, Almeida K, Das Neves RN, Dos Santos B, Stefanes NM, et al. Bishop Omics-based identification of an NRF2-related auranofin resistance signature in cancer: Insights into drug repurposing. Comput. Biol. Med [Internet]. 2023; 152:106347.
Feuser PM, Matos dos Santos PC, Cordeiro AP, Stefanes NM, Walter LO, Maioral MF, Santos-Silva MC, et al. Antineoplastic activity of free 4-nitrochalcone and encapsulated in poly(thioether-ester) nanoparticles obtained by thiol-ene polymerization in two human leukemia cell lines (Jurkat and K562). J Drug Deliv Sci Technol [Internet]. 2022; 67:102924.
Jacques AV, Stefanes NM, Walter LO, Perondi DM, Efe FL, Souza LFS, Sens L, et al. Synthesis of chalcones derived from 1-naphthylacetophenone and evaluation of their cytotoxic and apoptotic effects in acute leukemia cell lines. Bioorg. Chem [Internet]. 2021; 116:105315.
Duarte BF, Vieira DSC, Lisboa ML, Stefanes NM, Grando LJ, Santos-Silva MC. Características clínico-epidemiológicas de pacientes portadores de carcinoma de células escamosas de boca. Arquivos Catarinenses de Medicina. 2021; 50(2): 232–245.
Machado V, Jacques AV, Stefanes NM, Santos-Silva MC, Biavatti MW. Anti-leukemic activity of semisynthetic derivatives of Lupeol. Nat. Prod. Res. 2021; 35(22):4494-4501.
Bigolin A, Maioral MF, Stefanes NM, Mascarello A, Chiaradia-Delatorre LD, Nunes RJ, Yunes RA, et al. A novel sulfonamide derivative as a strong and selective apoptotic agent against hematological malignancies. Chem. Pap. 2020; 74:2965–2976.
Bigolin A, Maioral MF, Stefanes NM, Zatelli GA, Philippus AC, Falkenberg MB, Santos-Silva MC. Cytotoxic mechanisms of primin, a natural quinone isolated from Eugenia hiemalis, on hematological cancer cell lines. Anticancer Drugs. 2020; 31(7):709-717.
Maioral MF, Stefanes NM, Neufeldt PD, Chiaradia-Delatorre LD, Nunes RJ, Santos-Silva MC. Aldehyde biphenyl chalcones induce immunogenic apoptotic-like cell death and are promising new safe compounds against a wide range of hematologic cancers. Future Med. Chem. 2020; 12(8):673–688.
Perondi DM, Jacques AV, Stefanes NM, Maioral MF, Sens L, Pacheco LA, Cury NM, et al. A novel thiosemicarbazone as a promising effective and selective compound for acute leukemia. Anticancer Drugs. 2019; 30(8):p 828-837.
Rengifo AFC, Stefanes NM, Toigo J, Mendes C, Argenta DF, Dotto MER, Santos-Silva MC, et al. PEO-chitosan nanofibers containing carboxymethyl-hexanoyl chitosan/dodecyl sulfate nanoparticles loaded with pyrazoline for skin cancer treatment. Eur. Polym. J. 2019; 119:335-343.
Rengifo AFC, Stefanes NM, Toigo J, Mendes C, Santos-Silva MC, Nunes RJ, Parize AL, et al. A new and efficient carboxymethyl-hexanoyl chitosan/dodecyl sulfate nanocarrier for a pyrazoline with antileukemic activity. Mater. Sci. Eng. C [Internet]. 2019; 105:110051.
Maioral MF, Stefanes NM, Bigolin A, Zatelli GA, Philippus AC, Falkenberg MB, Santos-Silva MC. Miconidine acetate, a new selective and cytotoxic compound with synergic potential, induces cell cycle arrest and apoptosis in leukemia cells. Invest. New Drugs. 2019; 37:912–922.
Srefanes NM, Toigo J, Maioral MF, Jacques AV, Chiaradia-Delatorre LD, Perondi DM, Ribeiro AAB, et al. Synthesis of novel pyrazoline derivatives and the evaluation of death mechanisms involved in their antileukemic activity. Bioorg. Med. Chem. 2019; 27(2):375-382.
Maioral MF, Bodack CN, Stefanes NM, Bigolin A, Mascarello A, Chiaradia-Delatorre LD, Yunes RA, et al. Cytotoxic effect of a novel naphthylchalcone against multiple cancer cells focusing on hematologic malignancies. Biochim. 2017; 140:48-57.
You can view some of Dr Natália’s work below and links to her professional profile below.
Research Gate: https://www.researchgate.net/profile/Natalia-Stephanes
Linkedin: https://www.linkedin.com/in/nataliamarceli/
Does Lisinopril increase urination?
No, Lisinopril is not associated with increased urination as a side effect. This antihypertensive has no diuretic effect and it generally does not affect your urine output.
In fact, one of the rare side effects of Lisinopril is decreased urination and it is more common in people who have been using this antihypertensive for a long period of time.
Long-term users are also susceptible to kidney damage, which can also affect their urine output. Make sure you monitor your side effects and report them to your healthcare provider.
What side effects are common with Lisinopril?
Lisinopril does not cause frequent urination, but it is associated with some side effects. These include (1,2):
Common side effects
- Dizziness
- Headache
- Cough
- Fatigue
- Nausea
- Upset stomach
- Bloating
- Diarrhoea
- Rash or skin itching
- Low blood pressure (hypotension)
- Changes in taste sensation
Rare side effects (affecting less than 1% of individuals):
- Angioedema: Swelling of the face, lips, tongue, throat, or extremities, which can be serious and require immediate medical attention (3,4).
- Hyperkalemia: Elevated levels of potassium in the blood, which can cause abnormal heart rhythms.
- Renal impairment: Impaired kidney function or worsening of existing kidney problems.
- Neutropenia: A decrease in white blood cell count, which can increase the risk of infections.
- Liver dysfunction: chronic liver damage, although it is rare ().
- Pancreatitis: Inflammation of the pancreas, which can cause severe abdominal pain (5).
- Hypersensitivity reactions: Allergic reactions characterized by rash, fever, joint pain, or other symptoms.
- Blood disorders: Rare cases of blood-related disorders, such as thrombocytopenia or anaemia.
As stated earlier, renal impairment caused by Lisinopril may affect urination. In such cases, urinary retention is more commonly reported than frequent urination.
However, renal impairment with Lisinopril is quite rare and there could be other factors contributing to it, like an underlying kidney disease. Lisinopril may also indirectly cause mood-related side effects in some individuals.
What to do if you are experiencing increased urination?
Talk to your healthcare provider if you are experiencing increased urination without any apparent reason. Your doctor may suggest some tests to diagnose the functioning of your kidneys and bladder and rule out any underlying renal disease.
Just make sure you do not stop taking Lisinopril without consulting your doctor first. There is a reason why high blood pressure is known as a silent killer and it should be managed properly to prevent more complicated health conditions, especially cardiac illnesses.
Was this helpful?
References
1.-
Olvera Lopez E, Parmar M, Pendela VS, Terrell JM. Lisinopril. 2023 Jan 17. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. PMID: 29489196. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482230/
2.-
Goyal A, Cusick AS, Thielemier B. ACE Inhibitors. 2022 Jul 12. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. PMID: 28613646. Available from: https://www.ncbi.nlm.nih.gov/books/NBK430896/
3.-
Ulmer JL, Garvey MJ. Fatal angioedema associated with lisinopril. Ann Pharmacother. 1992 Oct;26(10):1245-6. doi: 10.1177/106002809202601012. PMID: 1330096. Available from: https://pubmed.ncbi.nlm.nih.gov/1330096/
4.-
Shahani L. ACE inhibitor-induced intestinal angio-oedema: rare adverse effect of a common drug. BMJ Case Rep. 2013 Jul 22;2013:bcr2013200171. doi: 10.1136/bcr-2013-200171. PMID: 23878294; PMCID: PMC3736615. Available from: https://pubmed.ncbi.nlm.nih.gov/23878294/
5.-
Droste HT, de Vries RA. Chronic hepatitis caused by lisinopril. Neth J Med. 1995 Feb;46(2):95-8. doi: 10.1016/0300-2977(94)00058-h. PMID: 7885528. Available from: https://pubmed.ncbi.nlm.nih.gov/7885528/
